C2N Diagnostics is a private company focused on diagnostics for Alzheimer’s disease and related neurodegenerative conditions. It offers Precivity blood tests to help providers assess amyloid plaque presence and also provides biomarker screening and monitoring tools for dementia clinical studies.
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07041450 |
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers |
RECRUITING | |
| NCT06856681 |
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease |
WITHDRAWN | NA |
| NCT06025877 |
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey |
ACTIVE_NOT_RECRUITING | |
| NCT05477056 |
Quality Improvement PrecivityAD Clinician Survey (QUIP I) |
COMPLETED | |
| NCT02494024 |
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy |
COMPLETED | PHASE1 |
